Verona Pharma plc clinical trials
Acquired by Merck & Co., Inc, Oct 7, 2025 · source ↗
The registry lists 19 studies whose lead sponsor is Verona Pharma plc. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 3, 2026.
- 19studies on the registry
- 1open to participants now
- 2reach primary completion within a year
Before and after it joined Merck & Co., Inc
- First submitted before Verona Pharma plc became part of Merck & Co., Inc
- 19
- First submitted after Verona Pharma plc became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Verona Pharma plc’s studies test, most studies first; none is open now — 4 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- ensifentrine3 in phase 30 open · 14
- 0 open · 3
- 0 open · 1
- 0 open · 1
Coming up
2 of Verona Pharma plc’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- 1MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- 1SSep
- OOct
- NNov
All 2
Add all 2 to your calendar (.ics) → With an account.
All 19 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 14
- 15
- 16
- 317
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Verona Pharma plc13 studies
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA5 studies
- Verona Pharma Inc1 study
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 19 of 19. All Merck & Co., Inc studies →
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisRecruitingNCT06559150Phase 2
Sponsor listed in the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA · First submitted before Verona Pharma, Inc. became part of Merck & Co., Inc
- Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)Active, not recruitingNCT05270525Phase 2
Sponsor listed in the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA · First submitted before Verona Pharma, Inc. became part of Merck & Co., Inc
- Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)CompletedNCT07016412Phase 2
Sponsor listed in the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA · First submitted before Verona Pharma, Inc. became part of Merck & Co., Inc
- A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPDCompletedNCT06545500Phase 2
Sponsor listed in the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA · First submitted before Verona Pharma, Inc. became part of Merck & Co., Inc
- A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT07132983Phase 2
Sponsor listed in the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA · First submitted before Verona Pharma, Inc. became part of Merck & Co., Inc
- Effect of Ensifentrine Treatment on CAT ScoreCompletedNCT06460493Phase 3
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- A Study of RPL554 in Patients With Cystic FibrosisCompletedNCT02919995Phase 2
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDCompletedNCT04535986Phase 3
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDCompletedNCT04542057Phase 3
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder InhalerCompletedNCT04027439Phase 2
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19CompletedNCT04527471Phase 2
Sponsor listed in the registry: Verona Pharma Inc · First submitted before Verona Pharma Inc became part of Merck & Co., Inc
- A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary DiseaseCompletedNCT04091360Phase 2
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPDCompletedNCT03937479Phase 2
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPDCompletedNCT03673670Phase 2
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT03443414Phase 2
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- The Effects of RPL554 in Addition to Tiotropium in COPD PatientsCompletedNCT03028142Phase 2
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- Comparison of RPL554 With Placebo and Salbutamol in Asthmatic PatientsCompletedNCT02427165Phase 2
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- The Effects of RPL554 on Top of Standard COPD Reliever MedicationsCompletedNCT02542254Phase 2
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc
- SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsCompletedNCT02307162Phase 1
Sponsor listed in the registry: Verona Pharma plc · First submitted before Verona Pharma plc became part of Merck & Co., Inc